Quoin Pharmaceuticals Receives FDA Fast Track Designation For QRX003 Lotion To Advance Treatment For Netherton Syndrome

Quoin Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company developing treatments for rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its product candidate QRX003 lotion (4%). This investigational therapy is being developed for Netherton Syndrome, a rare and serious genetic skin disorder that currently has no FDA-approved treatment options.

The company shared that this designation represents an important step forward for patients who are living with the daily challenges of Netherton Syndrome. According to Dr. Michael Myers, CEO and Co-Founder of Quoin Pharmaceuticals, the Fast Track status underscores the significant unmet medical need in this patient community. He noted that the designation allows the company to have more frequent and direct communication with the FDA and may open pathways for accelerated regulatory review. This could potentially shorten the time it takes to bring QRX003 to patients as the first approved therapy for the condition.

Quoin Pharmaceuticals is currently advancing QRX003 through two late-stage, whole-body clinical trials that are designed to evaluate both the safety and effectiveness of the lotion in individuals diagnosed with Netherton Syndrome. The company has already received multiple regulatory designations for QRX003. The therapy previously earned Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency (EMA), which may provide advantages such as market exclusivity after approval, tax credits for qualified clinical trials, and waivers or reductions of certain regulatory fees. In addition, the FDA has granted QRX003 Pediatric Rare Disease Designation, supporting its development for a condition that often affects children.

Netherton Syndrome itself is a rare inherited disorder caused by mutations in the SPINK5 gene. These mutations weaken the skin barrier, leading to chronic skin inflammation, persistent irritation, and increased vulnerability to infections and allergic reactions. Individuals with the disorder often experience symptoms such as extensive redness, scaling, intense itching, and overall discomfort that impacts daily life. Because no approved therapies currently exist, treatment typically focuses on supportive care, making the need for an effective, targeted therapy especially urgent.

Fast Track Designation is part of the FDA’s program to help speed up the development and review of drugs aimed at serious conditions with unmet medical needs. A therapy that receives this designation can benefit from closer communication with the FDA, rolling submission of regulatory documents, and potential eligibility for programs such as Accelerated Approval or Priority Review if the required criteria are met. By granting Fast Track status to QRX003, the FDA is recognizing both the severity of Netherton Syndrome and the need for a dedicated, clinically proven treatment option.